Santos André L S, Matteoli Filipe P, Gonçalves Diego S, Seabra Sergio H, Romanos Maria Teresa V, Branquinha Marta H, Resende Gabriel O, Cotrim Bruno A, Aguiar Lucia C S, Sangenito Leandro S
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Programa de Pós-Graduação em Bioquímica, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Parasitol Int. 2019 Dec;73:101968. doi: 10.1016/j.parint.2019.101968. Epub 2019 Aug 6.
The current treatments for leishmaniasis bump into several obstacles, including low efficacy, high costs, long monitoring, and several/severe side effects. Consequently, the search for promising compounds is a tangible need. Recently, we reported the anti-Leishmania amazonensis action of asymmetric peptidomimetic compounds containing tartaric acid as core, especially the 157 derivative that contains valine/leucine substituents in its structure. Herein, we decipher the multiple effects of 157 on the L. amazonensis physiology and on the interaction process with macrophages. The peptidomimetic 157 induced significant changes on the morphometric (internal granularity reduction as judged by flow cytometer) and on the ultrastructural (round-shaped parasites, presence of plasma membrane blebs and flagellum loss as visualized by scanning electron microscopy) aspects of treated promastigotes compared to untreated ones. The alteration on the plasma membrane permeability was confirmed by the passive incorporation of propidium iodide in 157-treated promastigotes. In parallel, the low viability of promastigotes was also associated to the perturbation of mitochondrial transmembrane electric potential. These combined results demonstrated that 157 induced irreversible metabolic damages that led to L. amazonensis death. The pre-treatment of promastigotes with 157 inhibited the association index with macrophages in a typically dose-dependent manner. Additionally, 157 significantly reduced the number of intramacrophage amastigotes after 72 h of drug contact, presenting an IC value of 30.2 μM. Under our experimental conditions, 157 showed higher toxicity to promastigotes and amastigotes when compared to RAW cells, resulting in good selective indexes. Therefore, 157 can be considered as an interesting candidate for further optimization, since its synthesis is simple and cheap.
目前治疗利什曼病的方法遇到了几个障碍,包括疗效低、成本高、监测时间长以及多种/严重的副作用。因此,寻找有前景的化合物是切实需要的。最近,我们报道了以酒石酸为核心的不对称拟肽化合物的抗亚马逊利什曼原虫作用,特别是其结构中含有缬氨酸/亮氨酸取代基的157衍生物。在此,我们解读了157对亚马逊利什曼原虫生理学以及与巨噬细胞相互作用过程的多重影响。与未处理的前鞭毛体相比,拟肽157在形态计量学(通过流式细胞仪判断内部颗粒度降低)和超微结构(圆形寄生虫、扫描电子显微镜观察到的质膜泡和鞭毛缺失)方面对处理过的前鞭毛体诱导了显著变化。碘化丙啶在157处理的前鞭毛体中的被动掺入证实了质膜通透性的改变。同时,前鞭毛体的低活力也与线粒体跨膜电位的扰动有关。这些综合结果表明,157诱导了不可逆的代谢损伤,导致亚马逊利什曼原虫死亡。用157预处理前鞭毛体以典型的剂量依赖性方式抑制了与巨噬细胞的结合指数。此外,药物接触72小时后,157显著减少了巨噬细胞内无鞭毛体的数量,IC值为30.2μM。在我们的实验条件下,与RAW细胞相比,157对前鞭毛体和无鞭毛体表现出更高的毒性,从而产生了良好的选择性指数。因此,157可以被认为是进一步优化的一个有趣候选物,因为其合成简单且成本低廉。